Prostate cancer study shows promise for future treatment
A new ‘seek-and-destroy’ gene therapeutic system could have the potential to treat prostate cancer in the future, after it halted the majority of tumours in laboratory models at the University of Strathclyde and the Beatson Institute.
The system was used against two types of prostate tumour, causing70 percent of one type and 50 percent of the other tovanish over a period of one month.These results are a promising start for the system as it continues its progress towards the clinic.
Prostate cancer is the fourth most widespread cancer in the world, the second most common in men and the most commonplace in Europe and North America. It causes the death of 300,000 patients worldwide each year and its incidence has continually increased over the last two decades.
The research has been published in the journal Drug Delivery. It involved researchers from Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde’s Department of Pure and Applied Chemistry and the Cancer Research UK Beatson Institute in Glasgow.
Dr. Christine Dufès, a Senior Lecturer in Strathclyde Institute of Pharmacy and Biomedical Sciences, led the research. She said: “Although some treatments, including chemotherapy and radiotherapy, can be effective against localised tumours, there is still no effective treatment for patients whose cancer recurs or spreads. This means that new therapeutic approaches are urgently needed for these patients.
“Gene therapy could be highly promising for the treatment of prostate cancer, but its use is currently limited by the lack of delivery systems which can selectively deliver the therapeutic genes to the tumours without adverse side effects for healthy tissues.
“To address this, we develop a new ‘seek-and-destroy’ nanomedicine linked to an iron-carrying protein called lactoferrin, whose receptors are found in large amounts in many cancers. The results show that it is highly promising for the treatment of prostate cancer by gene therapy.”
The research was carried out on two prostate cancer cell lines, PC-3 and DU145, in laboratory settings.
Source: Read Full Article